Trial · NCT00410813
Outcomes12
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 12 of 12
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Progression-free Survival | Up to 2 years | All eligible patients were included in this analysis. | weeks | MEDIAN |
| SECONDARY | Response Rate (Complete and Partial, Confirmed and Unconfirmed) | Up to 2 years | All eligible patients | participants | NUMBER |
| SECONDARY | MUC-1 Antigen Response | at 4, 8, 16, and 24 weeks | MUC-1 Inadequate Assessment, response unknown: MUC-1 response has not been adequately assessed at indicated timepoints. | ||
| SECONDARY | Circulating Tumor Cells (CTC) Response Rate | Up to 4 weeks | Treatment arms are combined in this analysis. Only eligible patients evaluated at both baseline and at 4 weeks were included. Patients analyzed for CTC response only includes patients who had elevated CTCs at baseline. | participants | NUMBER |
| SECONDARY | Change in Serum Bone Turnover Markers Over Time -- NTx | at baseline, 4, and 8 weeks | Number of patients with samples to analyze: baseline n=66, 4 weeks n=54, 8 weeks n=52. | nM BCE | MEAN |
| SECONDARY | Change in Serum Bone Turnover Markers Over Time -- BAP | at baseline, 4, and 8 weeks | Number of patients with samples to analyze: baseline n=66, 4 weeks n=54, 8 weeks n=52. | ug/L | MEAN |
| SECONDARY | Change in Serum Bone Turnover Markers Over Time | at baseline, 4, and 8 weeks | Number of patients with samples to analyze: baseline n=66, 4 weeks n=54, 8 weeks n=52. | pg/mL | MEAN |
| SECONDARY | Change in Serum Bone Turnover Markers Over Time -- OC | at baseline, 4, and 8 weeks | Number of patients with samples to analyze: baseline n=66, 4 weeks n=54, 8 weeks n=52. | ng/mL | MEAN |
| SECONDARY | Change in Serum Bone Turnover Markers Over Time -- OPG | at baseline, 4, and 8 weeks | Number of patients with samples to analyze: baseline n=66, 4 weeks n=54, 8 weeks n=52. | pmol/L | MEAN |
| SECONDARY | Change in Serum Bone Turnover Markers Over Time -- TRAP | at baseline, 4, and 8 weeks | Number of patients with samples to analyze: baseline n=66, 4 weeks n=54, 8 weeks n=52. | U/L | MEAN |
| SECONDARY | Number of Patients With Grade 3 Through 5 Adverse Events That Are Related to Study Drug | Up to 2 years | Eligible patients who received any treatment and were assessed for toxicity were included in the adverse event summaries. Any CTCAE v3.0 event of Grade 3 (severe), Grade 4 (life threatening), or Grade 5 (fatal) which were deemed to be related to protocol treatment are included. | Participants | NUMBER |
| SECONDARY | Mean Patient-reported Pain | Baseline, 8, 16, and 24 weeks | All patients with non-missing values were analyzed | units on a scale | MEAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00410813/outcomes